Phase II Trial Opens: Microbiome-Targeted Nutrition vs Placebo in Type 2 Diabetes — Novel Approach to Glycemic Control

References

1. 1.American Diabetes Association Professional Practice Committee. (2024). Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S1-S321. https://doi.org/10.2337/dc24-Sint
2. 2.Diabetes Control and Complications Trial Research Group. (2023). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329(14), 977-986. https://doi.org/10.1056/NEJM199309303291401
3. 3.Enbiosis Biotechnologies. (2024). A 24-Week Randomized, Masked, Placebo-Controlled Trial of an AI-Guided Microbiome-Targeted Nutritional Intervention for Glycemic Improvement in Adults With Type 2 Diabetes: The AIM-MET Trial. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07622628
4. 4.Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., ... & Pedersen, O. (2015). Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature, 528(7581), 262-266. https://doi.org/10.1038/nature15766
5. 5.Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D. B., Morgun, A., & Shulzhenko, N. (2020). Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine, 51, 102590. https://doi.org/10.1016/j.ebiom.2019.11.051
6. 6.Khunti, K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., ... & DISCOVER Study Group. (2021). Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism, 23(3), 706-718. https://doi.org/10.1111/dom.14262
7. 7.Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., ... & Wang, J. (2012). A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 490(7418), 55-60. https://doi.org/10.1038/nature11450